Interpace Diagnostics said today that Best Med Opinion will be the exclusive provider of its molecular diagnostic tests for Israel, through a partnership that will promote Interpace’s tests to physicians and patients.
The partnership covers Interpace’s three marketed tests: ThyGenX and ThyraMIR, both designed to determine the presence and absence of cancer in thyroid nodules; as well as PancraGEN, a pancreatic cyst molecular test.
Best Med has also agreed to manage logistics associated with collecting and shipping samples to the CLIA laboratories of Interpace when the tests are ordered, as well as to report results back to the ordering physician, Interpace said.
“We are excited about our relationship with Best Med. Their selection of our products and services is an important validation of our potential to expand internationally,” Interpace President and CEO Jack E. Stover said in a statement.
Citing growing interest in its tests, Interpace said it has established processes for logistics, specimen handling, and other key elements to address working with global partners.
Best Med is a provider of second opinion and clinical services for physicians and patients based in Israel. The company has developed a network of specialty providers in the U.S. and other countries that is designed to ensure all clinical options are known and explored in advance of treatment.
Best Med offers expertise in more than 40 specialties, including three focus areas served by Interpace’s tests—ear-nose-and-throat, endocrinology, and gastroenterology. Best Med said it opted for Interpace’s tests based on their clinical validity and utility as reported in peer-reviewed journals and other evidence, after evaluating several molecular diagnostic products.
“Their products fill an important role in our efforts to provide physicians and patients with access to the best diagnostic tools available to help inform treatment decisions,” added Best Med CEO Eran Lazar.
ThyGenX uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas. ThyraMIR, the first miRNA gene expression classifier, measures the expression of 10 miRNAs. PancraGEN uses a small sample of pancreatic cyst fluid to aid in pancreatic cancer risk assessment.